Thursday, February 9, 2012 Last update: 1:03 AM
The Best of U.S. Company Technology News
Now being accepted at FreshNews.com. See our complete guidelines.
Trade Events
CEL-SCI Corporation
News articles for CEL-SCI Corporation:
Friday, January 20, 2012
- CEL-SCI Corporation Releases Letter to ShareholdersThe following letter is being released by CEL-SCI Corporation (NYSE AMEX: CVM) to its shareholders: Dear Fellow Shareholders: ... read more
Friday, December 23, 2011
- CEL-SCI Corporation Announces Fiscal 2011 Financial ResultsCEL-SCI Corporation (NYSE AMEX: CVM) reported financial results today for the fiscal year ended September 30, 2011. CEL-SCI’s net loss available ... read more
Wednesday, November 2, 2011
- CEL- SCI Corporation Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection)CEL-SCI Corporation (NYSE AMEX: CVM) provided an update today of the progress of its Phase III clinical trial of Multikine (Leukocyte Interleukin, Injection)*, which is currently being ... read more
Friday, October 7, 2011
- CEL-SCI Corporation Announces the Closing of Its $4 Million Registered Direct Offering of Common Stock and WarrantsCEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has closed its previously announced registered direct offering for the sale of (i) 13,333,334 shares of its common stock ... read more
Thursday, September 15, 2011
- CEL-SCI’s Taiwanese Partner Orient Europharma Presents Development Strategies in Taiwan for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection) at World Orphan Drug ConferenceCEL-SCI Corporation (NYSE AMEX: CVM) announced that its Taiwanese partner Orient Europharma Co. Ltd. (“Orient Europharma”) today is presenting its development strategies for CEL-SCI's investigational ... read more
Tuesday, August 23, 2011
- CEL-SCI Announces Exclusive Sales, Marketing and Distribution Agreement for Its Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection) for Argentina and VenezuelaCEL-SCI Corporation (NYSE AMEX: CVM) today announced that it has entered into an exclusive Sales, Marketing and Distribution agreement with IDC-GP Pharm LLC (“IDC-GP Pharm”) under which CEL-SCI ... read more
Wednesday, August 17, 2011
- CEL-SCI Receives Key Chinese Patent for Its Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection)CEL-SCI Corporation (NYSE AMEX: CVM) today announced that the Chinese patent office has issued a key patent covering CEL-SCI’s investigational cancer drug, Multikine® ... read more